Anna Do, MD
Ophthalmology · San Diego, CANPI 1588058721
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 82.0% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2023 at $16,973 and has fallen 93.2% since, to $1,155 in 2025. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 163 payments — averaging $139.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$19K
- Alcon$746
- NEW World Medical,inc.$503
- Bausch & Lomb Americas Inc.$445
- Glaukos Corporation$347
- Johnson & Johnson Surgical Vision, Inc.$300
- plus $2K from 17 others
What the payments were for
- Consulting fees$1,3756%
- Speaking & faculty fees$12,82557%
- Travel & lodging$2,1469%
- Food & beverage$6,27628%
- Education$400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 67 | $18,572 |
| Alcon | 23 | $746 |
| NEW World Medical,inc. | 4 | $503 |
| Bausch & Lomb Americas Inc. | 8 | $445 |
| Glaukos Corporation | 4 | $347 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $300 |
| Aerie Pharmaceuticals, Inc. | 4 | $281 |
| Nova Eye, Inc. | 3 | $205 |
| Oyster Point Pharma, Inc. | 5 | $149 |
| Mallinckrodt Hospital Products Inc. | 6 | $142 |
| Rxsight Inc | 1 | $125 |
| Sight Sciences, Inc. | 7 | $122 |
| Sun Pharmaceutical Industries Inc. | 4 | $115 |
| Amgen | 5 | $114 |
| Ocular Therapeutix, Inc. | 3 | $99 |
| Thea Pharma Inc. | 4 | $86 |
| Lensar, Inc. | 1 | $76 |
| Biotissue Holdings Inc. | 3 | $74 |
| Tarsus Pharmaceuticals, Inc. | 2 | $47 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $47 |
| Novartis | 1 | $24 |
| Kala Pharmaceuticals, Inc. | 1 | $22 |
| Harrow Eye, LLC | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEN GLAUCOMA TREATMENT SYSTEM$17,188
- Tecnis IOL$281
- Ahmed Glaucoma Valve$159
- Kahook Dual Blade$159
- Clareon$144
- iDoseTR$137
- RXSIGHT CONTACT LENS$125
- RXSIGHT INJECTOR CARTRIDGE$125
- RXSIGHT INJECTOR HANDPIECE$125
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$125
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$125
- AcrySof IQ VIVITY IOL$121
- ScoutPro Osmolarity System$121
- Tecnis Simplicity$117
- enVista MX60 IOL$109
- VYZULTA$102
How this compares
$22,662 in reported general payments places this provider in the 90th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 82 | $106,970 |
| Cyclosporine | 80 | $59,418 |
| XiidraLifitegrast | 35 | $41,046 |
| VyzultaLatanoprostene Bunod | 56 | $36,415 |
| LumiganBimatoprost | 47 | $30,736 |
| RocklatanNetarsudil Mesylat/Latanoprost | 29 | $16,358 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 48 | $12,565 |
| Prednisolone Acetate | 201 | $8,976 |
| Timolol Maleate | 307 | $8,938 |
| Latanoprost | 667 | $8,590 |
| Alphagan PBrimonidine Tartrate | 12 | $7,356 |
| Travoprost | 58 | $7,330 |
| RhopressaNetarsudil Mesylate | 19 | $7,150 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 325 | $6,117 |
| Brimonidine Tartrate | 94 | $5,501 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P | $18,572 | $145,062141 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $445 | $77,46191 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $281 | $23,50848 claims |
| AlconSimbrinza | $746 | $4,70912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in San Diego
- Robert WeinrebSan Diego$520K
- Eric NudlemanSan Diego$343K
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.